Clinical trial NCT02676531: Walking Meditation Exercise in Breast Cancer Patients
Official title: Effects of Walking Meditation on Vascular Function in Breast Cancer Patients Receiving Anthracyclines Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: Walking Meditation
Vascular Function
Flow-mediated dilatation
Breast Cancer Patients
Anthracyclines Chemotherapy
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2016-02-08
Enrollment: 30
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study is to evaluate the effects of Walking Meditation on vascular function in breast cancer patients receiving Anthracyclines chemotherapy

Detailed description: Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking while listening to the sound "Budd" and "Dha" and squeeze rubber balls according to the sound in order to practice mindfulness while walking. In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set. In both phases of the training, the frequency of Walking Meditation training is three times a week.

Eligibility criteria: Inclusion Criteria:

1. The inclusion criteria included stage 1-2 of Breast cancer patients after an operation with or without Hormone Receptor Positive and HER2 Positive.
2. All participants will be planned to use Anthracyclines chemotherapy in next 1 month by oncologist.
3. All participants did not participate in any exercise training in the past 6 months
4. All participants are free from acute or chronic renal failure, Heart Failure, Myasthenia gravis, pregnancy and history of smoke.

Exclusion Criteria:

1. Participants will be excluded if they dropped out or completed less than 80% of the training schedule.

Primary outcomes:
measure: Change from baseline in vascular reactivity
timeFrame: baseline, up to 12 weeks
Secondary outcomes:
measure: Change from baseline in Intima-Media Thickness: IMT
timeFrame: baseline, up to 12 weeks
measure: Change from baseline in Peripheral arterial stiffness
timeFrame: baseline, up to 12 weeks
measure: Change from baseline in venous blood flow
timeFrame: baseline, up to 12 weeks
measure: Change from baseline in blood chemistry
timeFrame: baseline, up to 12 weeks
measure: Change from baseline in Maximal oxygen consumption
timeFrame: baseline, up to 12 weeks
measure: Change from baseline in Cardiac output and stroke volume
timeFrame: baseline, up to 12 weeks
measure: Change from baseline in Body Mass Index (BMI)
timeFrame: baseline, up to 12 weeks
measure: Change from baseline in stress indicators
timeFrame: baseline, up to 12 weeks
Other outcomes:
Locations:
city: Pathum Wan
country: Thailand
facility: Faculty of Sports Science, Chulalongkorn University
state: Bangkok
Study officials:
References: